Medicare Enrolled
Dr. James Lee, MD
Medical Oncology · Binghamton, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lee from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lee?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lee
Dr. James Lee is a medical oncology specialist in Binghamton, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lee performed 47,035 Medicare services across 2,423 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lee received a total of $45,094 from 77 pharmaceutical and/or device companies across 511 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lee is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in NY
$45,094 industry payments
Medicare Practice Summary
Medicare Utilization ↗47,035
Medicare services
Top 3% in NY for medical oncology
2,423
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,352 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
23,250 | $1 | $3 |
| Anti-nausea injection (aprepitant) | 7,670 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 3,780 | $18 | $65 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,604 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,271 | $1 | $5 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
984 | $8 | $75 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
925 | $7 | $100 |
| Anti-nausea injection (ondansetron/Zofran) | 888 | $0 | $2 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
757 | $10 | $100 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
660 | $77 | $540 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
550 | $11 | $100 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
546 | $92 | $335 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
303 | $96 | $500 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
220 | $56 | $300 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
205 | $62 | $229 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
201 | $10 | $100 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
133 | $6 | $75 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
114 | $2 | $9 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
111 | $9 | $100 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
108 | $22 | $150 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
95 | $48 | $175 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
83 | $1 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
67 | $130 | $446 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
54 | $49 | $250 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
52 | $6 | $100 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
52 | $18 | $150 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
50 | $14 | $100 |
| New patient office visit, complex (60-74 min) | 49 | $164 | $651 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
41 | $93 | $238 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
38 | $15 | $150 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
37 | $18 | $150 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
36 | $64 | $350 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
35 | $135 | $458 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
31 | $27 | $200 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
18 | $24 | $150 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
17 | $3 | $7 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
50.8% high complexity
40.6% medium
8.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$45,094
Total received (2018-2024)
Avg $6,442/year across 7 years
Top 27% in NY for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
77
Companies
511
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,489 (49.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12,339 (27.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$10,266 (22.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$19,417
2023
$2,404
2022
$4,330
2021
$3,388
2020
$728
2019
$607
2018
$14,221
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
JAZZ PHARMACEUTICALS INC.
$9,347
Gilead Sciences, Inc.
$7,849
ABBVIE INC.
$207
Daiichi Sankyo Inc.
$174
E.R. Squibb & Sons, L.L.C.
$170
PFIZER INC.
$168
Merck Sharp & Dohme LLC
$158
Astellas Pharma US Inc
$109
Genentech USA, Inc.
$103
Novartis Pharmaceuticals Corporation
$102
Takeda Pharmaceuticals U.S.A., Inc.
$77
Incyte Corporation
$74
Celgene Corporation
$74
Janssen Biotech, Inc.
$70
PUMA BIOTECHNOLOGY, INC.
$66
Genmab U.S., Inc.
$60
GlaxoSmithKline, LLC.
$57
Blueprint Medicines Corporation
$55
Sumitomo Pharma America, Inc.
$41
Exelixis Inc.
$40
ARRAY BIOPHARMA INC
$40
Karyopharm Therapeutics Inc.
$34
ADC Therapeutics America, Inc.
$31
Stemline Therapeutics Inc.
$28
Lilly USA, LLC
$25
Ipsen Biopharmaceuticals, Inc
$24
BeiGene USA, Inc.
$24
AstraZeneca Pharmaceuticals LP
$23
Adaptive Biotechnologies Corporation
$23
RECORDATI_RARE_DISEASES_INC.
$22
PharmaEssentia USA Corporation
$18
Regeneron Healthcare Solutions, Inc.
$17
TAIHO ONCOLOGY, INC.
$17
SERVIER PHARMACEUTICALS LLC
$17
Eisai Inc.
$17
GENZYME CORPORATION
$15
Kite Pharma, Inc.
$14
Alexion Pharmaceuticals, Inc.
$14
Aveo Pharmaceuticals, Inc.
$14
Top 3 companies account for 89.6% of 2024 payments
All-time payments by company (2018-2024) ›
AbbVie, Inc.
$10,615
JAZZ PHARMACEUTICALS INC.
$9,381
Gilead Sciences, Inc.
$7,894
Incyte Corporation
$3,040
Regeneron Healthcare Solutions, Inc.
$2,320
Merck Sharp & Dohme Corporation
$1,662
Janssen Research & Development, LLC
$1,351
AstraZeneca Pharmaceuticals LP
$749
E.R. Squibb & Sons, L.L.C.
$621
PFIZER INC.
$557
Novartis Pharmaceuticals Corporation
$485
Genentech USA, Inc.
$434
Janssen Biotech, Inc.
$420
Merck Sharp & Dohme LLC
$408
Takeda Pharmaceuticals U.S.A., Inc.
$367
Astellas Pharma US Inc
$280
ABBVIE INC.
$260
GENZYME CORPORATION
$243
Daiichi Sankyo Inc.
$240
GlaxoSmithKline, LLC.
$226
Celgene Corporation
$216
Lilly USA, LLC
$184
Karyopharm Therapeutics Inc.
$161
Seagen Inc.
$150
AstraZeneca UK Limited
$125
PUMA BIOTECHNOLOGY, INC.
$124
Genmab U.S., Inc.
$119
Pharmacyclics LLC, An AbbVie Company
$116
Acrotech Biopharma LLC
$114
Amgen Inc.
$109
Myriad Genetic Laboratories, Inc.
$102
ABIOMED
$94
Clovis Oncology, Inc.
$84
PharmaEssentia USA Corporation
$81
Apellis Pharmaceuticals, Inc.
$79
TAIHO ONCOLOGY, INC.
$79
Pharmacyclics LLC, an AbbVie Company
$75
Ipsen Biopharmaceuticals, Inc
$74
Sun Pharmaceutical Industries Inc.
$74
EMD Serono, Inc.
$72
TESARO, Inc.
$70
Puma Biotechnology, Inc.
$68
Exelixis Inc.
$61
Boehringer Ingelheim Pharmaceuticals, Inc.
$61
ARRAY BIOPHARMA INC
$60
Alexion Pharmaceuticals, Inc.
$60
Blueprint Medicines Corporation
$55
Sumitomo Pharma America, Inc.
$54
Rigel Pharmaceuticals, Inc.
$47
ADC Therapeutics America, Inc.
$45
Deciphera Pharmaceuticals Inc.
$44
Kite Pharma, Inc.
$42
Eisai Inc.
$41
EAGLE PHARMACEUTICALS, INC.
$40
G1 Therapeutics, Inc.
$37
SERVIER PHARMACEUTICALS LLC
$37
Pharmacosmos Therapeutics Inc.
$36
Lexicon Pharmaceuticals, Inc.
$33
AbbVie Inc.
$33
Mirati Therapeutics, Inc.
$33
MorphoSys, US Inc.
$29
Janssen Pharmaceuticals, Inc
$29
Stemline Therapeutics Inc.
$28
Sobi, Inc
$24
BeiGene USA, Inc.
$24
Bayer HealthCare Pharmaceuticals Inc.
$23
Adaptive Biotechnologies Corporation
$23
SUN PHARMACEUTICAL INDUSTRIES INC.
$22
RECORDATI_RARE_DISEASES_INC.
$22
Kyowa Kirin, Inc.
$21
Foundation Medicine, Inc.
$18
Epizyme, Inc.,
$17
Partner Therapeutics, Inc.
$17
SANOFI-AVENTIS U.S. LLC
$16
SOBI, INC
$15
Aveo Pharmaceuticals, Inc.
$14
Seattle Genetics, Inc.
$13
Top 3 companies account for 61.8% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALPROLIX · ALUNBRIG · AYVAKIT · Alecensa · BAVENCIO · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · ELIQUIS · ELREXFIO · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Empaveli · Enhertu · Epkinly · Erivedge · Erleada · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · Gazyva · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Impella · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nplate · Nubeqa · OJJAARA · OPDIVO · ORGOVYX · Onivyde · Orserdu · PADCEV · PEMFEXY · PIQRAY · PRECISETUMOR · PROMACTA · Padcev · Perjeta · Polivy · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RYBREVANT · Rubraca · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SYLVANT · TAGRISSO · TALVEY · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xermelo · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (50%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
1
Per 100K population
0.5
County median income
$61,059
Nearest hospital
OUR LADY OF LOURDES MEMORIAL HOSPITAL, INC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lee is a mixed practice specialist, with above-average Medicare volume (top 3% in NY), with mixed engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lee experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Lee performed 23,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lee receive payments from pharmaceutical companies?
Yes. Dr. Lee received a total of $45,094 from 77 companies across 511 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lee's costs compare to other medical oncologists in Binghamton?
Dr. Lee's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lee) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Binghamton
Browse medical oncologists in Binghamton ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in NY
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in NY
Which NY medical oncologists receive the most from drug and device companies.
By company
AbbVie, Inc. Payments to Doctors
See all physicians who received payments from AbbVie, Inc.
By company
JAZZ PHARMACEUTICALS INC. Payments to Doctors
See all physicians who received payments from JAZZ PHARMACEUTICALS INC.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology